Abstract: Chitosan-dextran sulfate nanoparticles of acetazolamide were formulated by using the ionic gelation technique, and evaluated for different attributes like particle size, ζ potential, drug entrapment, particle morphology, in vitro drug release, and in vivo efficacy. Particle size was observed to be changed with the increment of the drug/polymer ratio. Sustained in vitro drug release was exhibited by the particulate formulation that followed the Korsmeyer-Peppas kinetic model. Drug release from nanoparticles was found to occur, as shown by the results, through a combination of dissolution and diffusion. The optimized formulation had a particle size of 172.3 nm and ζ potential of 36.46 mV. The particles had a spherical shape and polydispersity index of 0.257. Decrease in crystallinity of the drug was indicated by powder X-ray diffraction and differential scanning calorimetry studies, in the optimized nanoparticle formulation. Approximately 2.5 times higher transcorneal permeation of drug was observed across the excised goat cornea, in comparison to the aqueous solution of drug, without any corneal damage, during ex vivo transcorneal studies. In vitro mucoadhesion studies showed 91.59% mucoadhesion. The in vivo studies involving ocular hypotensive activity in rabbits revealed significantly higher hypotensive activity with a p-value of < 0.05, in contrast to a plain drug solution, with no signs of ocular irritation.
Introduction
Increase in intraocular pressure (IOP) occurs in cases of glaucoma and is used to explain a group of ophthalmic disorders. A consistent increase in IOP may result in optic disc damage and disturbances in the visual field. An imbalance between aqueous humor drainage and production results in increased IOP. Agents used for treating glaucoma are intended to decrease the IOP either by limiting aqueous humor production in the ciliary body and/or by increasing aqueous humor outflow through the trabecular meshwork or the uveoscleral pathway. Various classes of drugs used in the long-term management of glaucoma include β-adrenergic blockers, miotics, adrenergic agonists, carbonic anhydrase inhibitors, prostaglandin analogues, and hyperosmotics [1] . Acetazolamide (AZ; a carbonic anhydrase inhibitor) ( Figure 1 ) is used for the reduction of IOP in patients suffering from glaucoma. High oral doses of AZ are given to effectively lower the IOP, which ultimately results in a variety of complications, e.g. diuresis, systemic acidosis, and sometimes also severe dyscrasias. The harmful systemic side effects of AZ could be avoided by using topical ocular formulations of AZ [2] . Most patients are unable to endure the systemic side effects due to large oral doses of AZ, and hence they break off the therapy [3] . The constraints in the development of topical AZ formulations are its poor solubility and its limited corneal penetration (log P = 0.3). These days, in the development of a new topical ocular formulation, great consideration is given toward new drug delivery systems that can ensure a localized effect and provide the convenience of a drop with enhanced corneal permeability of poorly permeable drugs [4] .
Materials and methods

Material
AZ, chitosan (CS) high molecular weight (CS-HMW), and CS low molecular weight (CS-LMW) were purchased from Sigma Aldrich (India). Dextran sulfate (DS) was purchased from High Media (India), and mannitol was purchased from SD-Fine (India).
Methods
Preparation of CS and DS solutions
CS (HMW and LMW) was dissolved in different concentrations (1, 2, and 3 mg/ml) in 1% acetic acid aqueous solution to yield solutions of CS at final concentrations of 0.1%, 0.2%, and 0.3%. On the other hand, an aqueous solution of DS of concentration 0.1% was finalized for preparing nanoformulations.
Formulation of AZ-loaded nanoparticles (NPs)
NPs were obtained by slow addition of 4 ml DS solution to 10 ml CS (HMW and LMW) under continuous magnetic stirring (1000 rpm) at room temperature. The NPs were instantaneously formed by the mechanism of ionotropic interaction of CS with polyanions of DS. Magnetic stirring was continued for 2 h at room temperature for system stabilization. The NPs so obtained were then lyophilized (Allied Frost, New Delhi, India) after the addition of 5% mannitol as cryoprotectant, and stored for further analysis. For 
Characterization of NPs
Percent drug entrapment
Lyophilized NPs (10 mg) were suspended in 10 ml distilled water by sonication in an ultrabath sonicator (Metrex). This suspension was then centrifuged (Remi) at 13,248 g for 30 min, and the supernatant was analyzed for the drug content by using an in-house developed and validated high-performance liquid chromatography (HPLC) method at 265 nm, having a linearity range, limit of detection, and limit of quantitation of 20-120 μg/ml, 37.60 ng/ml, and 0.11396 μg/ml, respectively. For the analysis of AZ by means of HPLC, a C8H column (250 × 4.6 mm) was used as the stationary phase and potassium dihydrogen phosphate buffer (pH 3), acetonitrile, and water at a ratio of 30:20:50 was used as the mobile phase with a flow rate of 0.8 ml/min, injection volume of 20 μl, run time of 10 min, and optimized retention time (RT) of 6.8 [5] . The entrapment efficiency was then calculated by using the following equation: 
Particle size and ζ potential
A dispersion of lyophilized NPs in water was sonicated for 30 s. Particle size, ζ potential, and the polydispersity index (PDI) were then analyzed by using Zetasizer Nano ZS-90 (Malvern, UK) attached with DTS software. The mean of three independent sample observations was reported.
2.2.3.3
Particle morphology (transmission electron microscopy -TEM) TEM (FEI, Netherlands) was used for morphological evaluation of the freeze-dried NPs. The sample was dried over copper grids at 25±2°C, without staining, and then observed under the electron beam of the TEM instrument.
Powder X-ray diffraction (PXRD) studies
A Bruker D8, Discover, X-ray diffractometer, with a Cu radiation source (3 kV), was used to observe the PXRD patterns of the samples within a 5-40° 2θ diffraction angle range.
Fourier transform infrared-attenuated total
reflection (FTIR-ATR) studies An FTIR-ATR spectrophotometer (Bruker) was used to record the infrared (IR) spectra of samples, in the range of 4000-400 cm -1 .
Differential scanning calorimetry (DSC)
A DSC TA-60 (Shimadzu, Tokyo, Japan) calorimeter was used. Samples were sealed in aluminum pans and heated at a rate of 10°C/min for a temperature range of 40°C to 300°C, keeping a blank aluminum pan as the reference pan. The flow rate of nitrogen was maintained at 50 ml/min.
In vitro drug release
For in vitro studies, 1 ml of freshly prepared nanosuspension/drug solution equivalent to 0.1% of drug was sealed in a dialysis membrane tube (High Media) with the help of dialysis closure clips (High Media), and made to sink in a beaker containing 100 ml Sorenson phosphate buffer (pH 7.4), which served as dissolution medium. The dissolution medium was stirred continuously with the help of a Teflon-coated magnetic bar at a speed of 50 rpm. Thereafter, samples of 5 ml volume were withdrawn at the specific time intervals (30, 60, 120, 180, 240, 360, and 480 min) and replaced with the fresh dissolution medium for maintaining the sink conditions. The samples withdrawn were then analyzed by using the HPLC method at 265 nm [6] .
Ex vivo transcorneal permeation
A modified Franz diffusion cell was used for studying permeation across an excised goat cornea. Intact eyeballs of goat were obtained from a local slaughterhouse (Khanpur, Delhi, India) within 1 h of slaughtering of the animal. The cornea was then carefully removed from the eyeball, leaving an extra 2-4 mm of epithelial membrane around the cornea, for the proper mounting over the diffusion cell. The cornea was then mounted over the modified diffusion cell, keeping the epithelial membrane toward the donor compartment. The receptor chamber was filled with 10 ml Sorenson phosphate buffer (pH 7.4); the donor chamber contained 1 ml of nanosuspension/solution equivalent to 0.1% of drug. After 2 h, the sample was withdrawn from the receptor compartment and analyzed for the drug content permeated, by using the HPLC method at 265 nm. The percent drug permeation was calculated by using the following equation:
% Corneal permeation Amount of drug permeated in the receptor chamber 100.
Initial amount of drug in the donor compartment
Percent corneal hydration was also calculated after cutting the extra 2 mm epithelial tissue and keeping the cornea in a hot air oven at 90°C overnight after moistening in 1 ml methanol. The percent corneal hydration was calculated by using the following equation [7] :
Weight of moist cornea -weight of dried cornea 100. Weight of moist cornea
In vivo studies
Ocular hypotensive efficacy
The approval of the Institutional Animal Ethics Committee was obtained for the experimental protocol, for conducting in vivo studies. The in vivo study was conducted to compare the ocular hypotensive activity of the optimized nanoformulation with that of the aqueous solution having the same drug concentration (0.1%) as that of the nanoformulation. Normotensive rabbits were used to compare the ocular hypotensive activity. A group of three animals weighing 2-2.5 kg was used for each study. Access to food and water was made free for the animals, housed in the institutional animal house, under standard conditions. Each rabbit of the control group (group I) was instilled with 50 μl normal saline (0.9% w/v) vehicle, while group II and group III animals were instilled with 50 μl AZ (0.1%, w/v) ophthalmic solution in normal saline or 50 μl AZ (0.1%, w/v) nanosuspension in normal saline, respectively. The IOP was measured in conscious rabbits with the help of a Schiotz tonometer, using 2% lignocaine HCl (50 μl) solution as a local anesthetic. Before instillation of the formulation (aqueous solution/nanoformulation) in the ocular chamber of the rabbits, the resting IOP of each animal was recorded. The dose of AZ to be administered was fixed to 1 mg in both the nanoformulation as well as in the aqueous solution. A single 50 μl drop of the formulation (aqueous solution/nanoformulation), having a drug concentration of 0.1%, was instilled into the experimental eye and this time point was recorded as time 0. Thereafter, the IOP was measured at different time intervals (0.5, 1, 2, 3, 4, and 5 h). The change in IOP (ΔIOP) was determined by using the following equation [8, 9] : dosed eye c ontrol eye
Determination of the ocular irritation index
A modified Draize test was used for ocular irritancy on a group of three New Zealand albino rabbits. In the lower cul-de-sac of the eye of each animal, 50 μl nanoformulation was instilled, with the help of a needleless syringe. The untreated contralateral eye was used as a control. To prevent the loss of dropped solution from the eyes, the eyelids were held, in a gentle manner, for 10 s. Ocular reactions like redness, discharge, conjunctival chemosis, and iris and corneal lesions were observed in the animals' eyes, at different time intervals (5, 10, 15, and 30 min and 1, 2, 3, 6, 9, 12, and 24 h) after instillation. The ocular irritancy test was performed by providing 0 (absence) to 4 (highest) grades on the clinical evaluation scale. The total clinical score, at different observation time points, was determined to calculate the overall ocular irritation index (Iirr). Clinically significant irritation was indicated by a score of 2 or 3 in any category or Iirr > 4. The observations regarding the ocular irritation were noted for normal saline-and AZ-loaded optimized nanoformulations [10] .
Ex vivo mucoadhesion studies
A pig mucin (Himedia, Mumbai, India) suspension was prepared in 0.05 m saline phosphate buffer (pH 7.4). Placebo CS NPs and drug-loaded CS NPs were mixed with 1 ml mucin suspension and incubated at 37°C for 30 min and kept for 24 h at room temperature. The samples were centrifuged in a cooling centrifuge (12,000 rpm, 30 min); the supernatant was collected; and free pig mucin was quantified by using a UV spectrophotometer (Perkin Almer) at 251 nm. The binding efficiency of mucin with CS NPs was calculated by using the following equation [11] :
Stability studies on optimized formulation
Accelerated stability study conditions, i.e. 40°C and 75% relative humidity (RH), were imposed on the lyophilized nanoformulation after packing in screw-capped glass bottles wrapped with aluminum foil, and samples were withdrawn at different time intervals (0, 1.5, 3, and 6 months) for determining drug content for long term stability studies. The lyophilized nanoformulation was stored at room temperature, and samples were withdrawn at different time intervals (0, 3, 6, and 12 months).
Statistical analysis
The whole data were statistically analyzed by using GraphPad Prism 5 software (GraphPad Software Inc., San Diego, CA, USA), and p < 0.05 was considered significant. The adopted statistical methods include ANOVA followed by Dunnett's test or Student's t-test.
Results and discussion
Percent drug entrapment
In the present study, the percent drug entrapment (±SD) for the AD1, AD2, and AD3 formulations was found to be 56.23±0.090, 53.32±0.030, and 38.53±0.023, respectively, and for AD4, AD5, and AD6, the percent entrapment was 62.45±0.05, 62.33±0.02, and 46.63±0.02, respectively. It was observed in formulations that as we increased the DS/CS ratio, the percent entrapment of acetazolmide decreased, and that is attributed to decreased relative DS concentration [12] .
Particle size and ζ potential
The polyelectrolyte ratio affects the ζ potential of NPs. Measurement of ζ potential is done to determine the surface charge of NPs. The ζ potential of NPs is greatly influenced by the composition of the particle and dispersion medium, and it also gives an idea about the electrical potential of the particles. The individual values for
Total mucin concentration mucin concentration in supernatant % Mucoadhesion 1 00. Total mucin concentration
particle size, ζ potential, and PDI of all the formulations are listed in Table 2 . The particle size of the formulations is within the range of 149.7-330.73 nm, whereas the ζ potential and PDI were found within the range of 12.43-36.46 and 0.257-0.362, respectively. All of the NPs were found to have a positive charge value, with the highest charge value of 36.46 for the AD2 formulation, whereas PDI is least (0.257), which is the indicator of good stability and dispersion homogeneity [13] . Also, as the corneal mucin layer is negatively charged, the positively charged NPs will be mucoadhesive and will increase the ocular bioavailability of the drug.
Particle morphology
The shape of the particles was analyzed by using TEM, which revealed a discrete spherical shape ( Figure 2 ). The TEM images revealed the particle size of the optimized formulation (AD2) to be < 200 nm. The result of TEM matched with the results of particle size measurement done with Zetasizer. The prepared particles were spherical or subspherical in shape, having a smooth surface devoid of cracks. Particles with sharp edges and angles cause more irritation as compared to isometric particles with obtuse angles and edges. Therefore, the optimized formulation is not supposed to cause irritation on the ocular surface [14] . Due to the strong surface charges, the particles are stabilized against agglomeration as they were observed separated from each other.
PXRD studies
The X-ray diffraction patterns of samples are presented in Figure 3 . AZ exhibited the characteristic diffraction peaks at 9.08°, 9.9°, 16 Sharp peaks, present in the diffraction pattern of AZ and mannitol, confirmed their crystalline structure, while the diffractograms of CS and DS indicated an amorphous structure. The diffractogram of the nanoformulation exhibited the significant peaks that were corresponding to the crystalline structure of mannitol, and no peaks corresponding to AZ was obtained, which indicated the drug's presence in the amorphous state inside the polymer [14] .
FTIR-ATR studies
The FTIR spectrum (Figure 4 . The mannitol spectrum showed peaks at 3394.12 cm -1 for OH stretching at 1419.19 cm -1 for OH in plane bending, at 1078.92 cm -1 for C = O stretching, and at 701 cm -1 for OH out-of-plane bending for alcohol. However, the spectrum of nanoformulations did not show any characteristic peak of AZ, which may be due to excess dilution of AZ. Figure 5 represents the DSC thermograms of different samples. AZ exhibited a sharp endotherm at 261°C corresponding to the melting point of AZ. The thermal curve of CS revealed a broad endotherm without any sharp peak, while the thermogram of DS showed an exotherm at 206.78°C. On the other hand, an endothermic peak at 167.04°C was observed for mannitol. A small endotherm at 167°C was displayed in the thermogram of nanoformulations (AD2) corresponding to the endothermic peak of mannitol, while no endotherm of the drug was observed indicating decreased crystallinity in the formulations or because of the very small quantity of drug in the freezedried formulation [14] . Figure 6 represents the comparative in vitro release profile of different CS-based nanosuspensions. The dialysis method was used for studying AZ release in Sorenson's phosphate buffer (pH 7.4), which served as the release medium. The NP formulations made with CS-LMW (AD1, AD2, and AD3) showed 43.81%, 39.20%, and 38.32% drug release, respectively, in 8 h. On the other hand, nanoformulations made with CS-HMW (AD4, AD5, and AD6) showed 45.83%, 44.45%, and 43.71% drug release, respectively, while from the 0.1% aqueous drug solution (control), 98.72% drug was diffused. The results suggest that entrapment of the drug in the NPs hinders drug release. On increasing the polymer concentration or increasing the drug/polymer ratio, sustained drug release was obtained. The optimized formulation showed initial burst release for the first 2 h of release study (22.52%), followed by sustained release. For determining the release mechanism and regression coefficients (R 2 ), different mathematical kinetic models like Korsmeyer-Peppas, Higuchi, Hixson Crowell, zero order, and first order were applied over the release data of the nanoformulations [15] . The release of AZ from CS NPs linked best to Korsmeyer-Peppas, which can be established by comparing the values for the regression coefficient (R 2 ) of zero order (0.8670), first order (0.8764), Higuchi (0.9480), Korsmeyer-Peppas (0.9674), and Hixson Crowell (0.8900). The diffusion exponent of the Korsmeyer-Peppas equation, i.e. "n" indicated that the release of AZ from CS NPs is by a dual mechanism of dissolution and diffusion, i.e. anomalous, as its value was found within the range of 0.5-1.0. The initial fast release of AZ can be attributed to the rapid hydration of NPs due to the hydrophilic nature of CS and DS, as well as the drug present on the surface of the particles. The sustained effect can be explained by the presence of drug within the core of the particles. The release medium penetrates into the particles and dissolves the entrapped drug, which further diffuses out into the dissolution media.
DSC
In vitro drug release
Ex vivo transcorneal permeation; percent corneal hydration
A 2.5 times enhanced transcorneal permeation (statistically significant, p < 0.05) of drug was observed with the optimized nanoformulation (AD2), across excised goat cornea, in comparison to the control formulation (0.1% aqueous solution) (Table 3, Figure 7 ). The possibly positive charge and small size contributed toward the enhanced corneal uptake. The normal range of corneal hydration (75-80%) was observed, which indicates the eye-friendly nature of the optimized formulation [16] .
In vivo ocular hypotensive efficacy studies
The observation suggested that the hypotensive activity of the drug-loaded NP formulation (AD2) was comparable to that of the plain drug solution (Figure 8 ). In case of plain AZ solution, the IOP was decreased for a period of 2 h and then started rising, whereas in case of nanoformulations this fluctuation was not observed: the IOP was below the normal level throughout the period of study, i.e. 5 h. The results suggested that the AZ-loaded nanoformulation produced a significant and prolonged reduction in IOP throughout 5 h. This overwhelming superiority over the plain AZ solution was further magnified when single instillation was considered.
Determination of ocular irritation index
The formulation was found non irritant as Iirr was found to be zero.
In vitro mucoadhesion studies
The mucoadhesive strength or bioadhesive force of CS NPs (AD2) was determined by the adsorption of CS NPs on pig mucin glycoprotein, and found to be excellent, i.e. 91.59±1.48% for AZ-loaded CS NPs. It is due to hydrogen bond formed between the positive-charge amino group of CS and the oligosaccharide chains of mucin [11] .
Stability studies
Under an accelerated condition (i.e. 40°C/75% RH) for 6 months, the nanoformulation (AD2) had 96.08% AZ content; on the other hand, the content was 95.21% after 12 months storage at room temperature. 
